Tango Therapeutics (NASDAQ:TNGX) Insider Sells $303,765.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 20,251 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00. Following the completion of the transaction, the insider owned 112,622 shares of the company’s stock, valued at $1,689,330. This trade represents a 15.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Adam Crystal also recently made the following trade(s):

• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total value of $226,221.52.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $16.99 on Thursday. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -19.53 and a beta of 1.76. The stock has a fifty day moving average price of $12.34 and a two-hundred day moving average price of $9.66. Tango Therapeutics, Inc. has a 52-week low of $1.03 and a 52-week high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. As a group, research analysts predict that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Institutional Trading of Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics in the 4th quarter valued at about $35,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after buying an additional 15,037 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after buying an additional 1,640 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Tango Therapeutics by 78.8% in the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock valued at $40,000 after buying an additional 3,452 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after acquiring an additional 4,464 shares during the last quarter. 78.99% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Wall Street Zen lowered shares of Tango Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Jefferies Financial Group reissued a “buy” rating and set a $18.00 price target on shares of Tango Therapeutics in a research note on Thursday, March 5th. Guggenheim raised their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Wolfe Research assumed coverage on shares of Tango Therapeutics in a research report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.